The Food and Drug Administration said it approved Akeega with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer, as determined by an FDA-approved test. Akeega is developed by Johnson & Johnson’s Janssen Biotech.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $197 from $190 at Morgan Stanley
- Johnson & Johnson price target raised to $230 from $209 at RBC Capital
- Johnson & Johnson price target raised to $232 from $215 at Citi
- Johnson & Johnson price target raised to $240 from $215 at HSBC
- Cautious Hold Rating for Johnson & Johnson Amid Promising Clinical Results and Competitive Challenges